Longitudinal data were analysed on the lung function of25 of29 survivors ofchildhood leukaemia or lymphoma, who had been conditioned with cyclophosphamide and total body irradiation before allogeneic bone marrow transplantation, to test whether children are particularly vulnerable to pulmonary damage after transplantation. None developed chronic graft-versus-host disease. Transfer factor and lung volumes were reduced immediately after bone marrow transplantation, but increased during the following years. However, at the last foliow up, 4-13 years (median 8) after transplantation, patients had significantly reduced transfer factor, total lung capacity, and forced vital capacity (-1*0, -1-2, and -0-8 SD score, respectively), and increased ratio of forced expiratory volume in one second to forced vital capacity (+0.9 SD score). None of the patients had pulmonary symptoms, and changes were unrelated to their age at bone marrow transplantation. In conclusion, patients had subclinical restrictive pulmonary disease at a median of eight years after total body irradiation and allogeneic bone marrow transplantation.
During the last two decades, allogeneic bone marrow transplantation has been used to treat children with relapsed or very high risk leukaemia and lymphoma. Many of these children become long term survivors,' so the late effects ofbone marrow transplantation have become increasingly important. Pulmonary complications are a major cause of post-transplant morbidity and mortality.26 There have been only a few reports of lung function in children after allogeneic7-9 or autologous bone marrow transplantation,'0 11 while several large studies have been published for adults.35 [12] [13] [14] The studies in adults have identified the dose, dose rate, and fractionation of total body irradiation as risk factors for restrictive lung disease. Chronic graft-versus-host disease (GVHD), greater age of the patient at bone marrow transplantation, and prolonged use of methotrexate for GVHD prophylaxis are risk factors for developing obstructive lung disease in adults. Since the lungs of children should grow after the bone marrow transplantation, conclusions for children cannot be drawn directly from studies on adults. One paediatric study confirmed chronic GVHD as a risk factor for obstructive lung disease,9 while four other studies, with a relatively short follow up, did not identify any risk factors.7 8 10 11 Thus, information about pulmonary function in children after bone marrow transplantation is sparse. We therefore analysed longitudinal data on lung function in a population based cohort treated with total body irradiation and allogeneic bone marrow transplantation for childhood leukaemia or lymphoma, to describe the changes over time and the outcome four to 13 years after bone marrow transplantation.
Methods

PATIENTS
Before 31 December 1990, 43 patients had been treated with allogeneic bone marrow transplantation for haematological malignancies diagnosed before the age of 15 while residing in East Denmark (population 2-4 million). Twenty five (86%) of the 29 patients who were alive in January 1992 (survival 67%) gave their informed consent to participate in the present study and are described in table 1. Twenty one participants had acute lymphoblastic leukaemia, two had acute myeloblastic leukaemia, one had chronic myelocytic leukaemia, and one had T cell non-Hodgkin's lymphoma. None received radiotherapy of the lungs before conditioning for bone marrow transplantation, but patients 4, 18, and 23 received spinal irradiation in midline doses of 20, 10, and 12 Gy, respectively, with the risk of scatter to the lungs.15 Seventeen participants received marrow from an HIA identical sibling, while the rest received marrow from other family donors. The median age at diagnosis, at bone marrow transplantation, and at the follow up pulmonary function test was 6-9 years (range 1 9 to 15-0), 11-3 years (5.7 to 17-6), and 17-2 years (11 6 to 26 5) respectively, and the median follow up time after bone marrow transplantation was 7-5 years (4-0 to . Twelve of the 25 participants developed acute GVHD of grade 2 or more, which means a rash on more than 25% of the body surface, or GVHD of the liver or gut. ' Our participants were so homogeneous that we could not test for any influence of interstitial pneumonia, chronic GVHD, type of malignancy, tobacco smoking, or type of GVHD prophylaxis on long term lung function. We could not relate changes in lung function to either the bone marrow transplantation procedure and its complications or to the malignancy and the pre-bone marrow transplantation treatment because we lacked pulmonary function tests before transplantation in most of the patients.
In conclusion, survivors of childhood leukaemia or lymphoma were asymptomatic but had a moderately restrictive pulmonary deficiency at a median of eight years (range four to 13) after total body irradiation and allogeneic bone marrow transplantation. The degree of restrictive pulmonary deficiency was not related to the age of the patient at transplantation. Lung function in some patients changed considerably several years after their transplants, so it will be of clinical importance to follow lung function in these patients long term.
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